Latest blog articles
-
On 30 May 2024, the Council of the European Union announced its final approval of the Union’s long anticipated withdrawal from what can fairly be labelled as the most controversial international treaty ever, the Energy Charter Treaty (ECT).
-
Last year’s COP28 has resulted in a ‘historic’ mention of fossil fuels in its final decision, be it in a rather limited way. Where does the EU, the forerunner in climate action, stand when it comes to the elimination of fossil fuels? This post highlights a few problematic features of the EU’s policy...
-
Questions surrounding how the EU budget is spent or audited have been, and will always be, of interest to EU citizens. Formally, the responsibility for the implementation of the budget rests with the Commission, but it is well known that the Member States have a crucial role to play, especially in...
-
On 4 March 2021, Italy decided to block a shipment of the Oxford/AstraZeneca Covid-19 vaccine that was destined for Australia. This remarkable move, notably made in response to AstraZeneca’s delay in providing the agreed doses of vaccines by the set deadlines, is the first of its kind since the...
-
How do we guarantee access to COVID-19 vaccines and therapies, and secure health-related human rights for all? We’ve heard a string of promises in the race for new vaccines and therapies.
-
It’s been almost a month since the COVID-19 pandemic has drastically changed the way we live and work. Now that we are more used to, in a manner of speaking, the extraordinary measures to curtail the rampant spread of the virus, it’s time to seriously consider, and openly discuss, this crisis’...
-
Administrative law, and specifically the law concerning judicial review of administrative action, has been regarded by doctrine until the second half of the twentieth century as a product of the national history and tradition of a state, and hence, because of the different national traditions, as an...
-
Globally the majority of health-related R&D is invested in medicines with substantial guaranteed returns, yet what is missing is extensive R&D targeted at diseases overwhelmingly prevalent in developing countries. This threatens long-term availability of medicines and treatment options for these...
-
On 6 June, IGIR fellow Dr. Iveta Alexovičová, Assistant Professor of International Economic Law, Faculty of Law, Maastricht University, delivered a lecture entilted "Substance alongside procedure - a lesson learned?".